Literature DB >> 33488516

Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.

Valentina Cirello1, Carla Colombo1,2, Olga Karapanou3, Gabriele Pogliaghi1, Luca Persani1,4, Laura Fugazzola1,2.   

Abstract

Several low penetration susceptibility risk loci or genes have been proposed in recent years with a possible causative role for familial non-medullary thyroid cancer (FNMTC), though the results are still not conclusive or reliable. Among all the candidates, here fully reviewed, a new extremely rare germline variant c.3607A>G (p.Y1203H) of the DUOX2 gene, has been recently reported to co-segregate with the affected members of one non-syndromic FNMTC family. We aimed to validate this finding in our series of 33 unrelated FNMTC Italian families, previously found to be negative for two susceptibility germline variants in the HABP2 and MAP2K5 genes. Unfortunately, the DUOX2 p.Y1203H variant was not found in either the 74 affected or the 12 not affected family members of our series. We obtained interesting data by comparing the clinico-pathological data of the affected members of our kindreds with a large consecutive series of sporadic cases, followed at our site. We found that familial tumors had a statistically significant more aggressive presentation at diagnosis, though not resulting in a worst outcome. In conclusion, we report genetic and clinical data in a large series of FNMTC kindreds. Our families are negative for variants reported as likely causative, namely those lying in the HABP2, MAP2K5 and DUOX2 genes. The extensive review of the current knowledge on the genetic risk factors for non-syndromic FNMTCs underlies how the management of these tumors remains mainly clinical. Despite the more aggressive presentation of familial cases, an appropriate treatment leads to an outcome similar to that observed for sporadic cases.
Copyright © 2021 Cirello, Colombo, Karapanou, Pogliaghi, Persani and Fugazzola.

Entities:  

Keywords:  DUOX2; FNMTC; HABP2; MAP2K5; familial non-medullary thyroid cancer; familial thyroid cancer; outcome

Year:  2021        PMID: 33488516      PMCID: PMC7817808          DOI: 10.3389/fendo.2020.589340

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  43 in total

1.  Does familial non-medullary thyroid cancer adversely affect survival?

Authors:  Frederic Triponez; Mariwil Wong; Cord Sturgeon; Nadine Caron; David G Ginzinger; Mark R Segal; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Familial nonmedullary thyroid carcinoma: a meta-review of case series.

Authors:  K C Loh
Journal:  Thyroid       Date:  1997-02       Impact factor: 6.568

4.  A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.

Authors:  Elly S W Ngan; Brian H H Lang; Tingting Liu; Cathy K Y Shum; Man-Ting So; Danny K C Lau; Thomas Y Y Leon; Stacey S Cherny; Sophia Y Tsai; Chung-Yau Lo; Ui-Soon Khoo; Paul K H Tam; Maria-Mercè Garcia-Barceló
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

5.  Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.

Authors:  M Capezzone; S Marchisotta; S Cantara; G Busonero; L Brilli; K Pazaitou-Panayiotou; A F Carli; G Caruso; P Toti; S Capitani; A Pammolli; F Pacini
Journal:  Endocr Relat Cancer       Date:  2008-10-02       Impact factor: 5.678

6.  The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer.

Authors:  Ruta Sahasrabudhe; Jacob Stultz; John Williamson; Paul Lott; Ana Estrada; Mabel Bohorquez; Claire Palles; Guadalupe Polanco-Echeverry; Emma Jaeger; Lynn Martin; Maria Magdalena Echeverry; Ian Tomlinson; Luis G Carvajal-Carmona
Journal:  J Clin Endocrinol Metab       Date:  2015-12-21       Impact factor: 5.958

7.  The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population.

Authors:  Artur Kowalik; Danuta Gąsior-Perczak; Martyna Gromek; Monika Siołek; Agnieszka Walczyk; Iwona Pałyga; Małgorzata Chłopek; Janusz Kopczyński; Ryszard Mężyk; Aldona Kowalska; Stanisław Góźdź
Journal:  Oncotarget       Date:  2017-04-06

8.  HABP2 G534E Variant in Papillary Thyroid Carcinoma.

Authors:  Jerneja Tomsic; Rebecca Fultz; Sandya Liyanarachchi; Huiling He; Leigha Senter; Albert de la Chapelle
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

9.  The HABP2 G534E polymorphism does not increase nonmedullary thyroid cancer risk in Hispanics.

Authors:  Mabel E Bohórquez; Ana P Estrada; Jacob Stultz; Ruta Sahasrabudhe; John Williamson; Paul Lott; Carlos S Duque; Jorge Donado; Gilbert Mateus; Fernando Bolaños; Alejandro Vélez; Magdalena Echeverry; Luis G Carvajal-Carmona
Journal:  Endocr Connect       Date:  2016-04-20       Impact factor: 3.335

10.  MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.

Authors:  Chiara Pesenti; Marina Muzza; Carla Colombo; Maria Carla Proverbio; Claudia Farè; Stefano Ferrero; Monica Miozzo; Laura Fugazzola; Silvia Tabano
Journal:  Endocrine       Date:  2017-12-06       Impact factor: 3.633

View more
  3 in total

Review 1.  Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.

Authors:  María Sánchez-Ares; Soledad Cameselle-García; Ihab Abdulkader-Nallib; Gemma Rodríguez-Carnero; Carolina Beiras-Sarasquete; José Antonio Puñal-Rodríguez; José Manuel Cameselle-Teijeiro
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-28       Impact factor: 5.555

2.  Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines.

Authors:  Daqi Zhang; Carla Colombo; Hui Sun; Hoon Yub Kim; Antonella Pino; Simone De Leo; Giacomo Gazzano; Luca Persani; Gianlorenzo Dionigi; Laura Fugazzola
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

3.  Identification of NID1 as a novel candidate susceptibility gene for familial non-medullary thyroid carcinoma using whole-exome sequencing.

Authors:  Luis Eduardo Barbalho de Mello; Thaise Nayane Ribeiro Carneiro; Aline Neves Araujo; Camila Xavier Alves; Pedro Alexandre Favoretto Galante; Vanessa Candiotti Buzatto; Maria das Graças de Almeida; Karina Marques Vermeulen-Serpa; Sancha Helena de Lima Vale; Fernando José de Pinto Paiva; José Brandão-Neto; Janete Maria Cerutti
Journal:  Endocr Connect       Date:  2022-01-31       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.